Pharmacy Medical News about Kidney Failure, Acute Natriuretic Peptides

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Atrial natriuretic peptide for preventing and treating acute kidney injury
Cochrane Reviews, 10/20/09

Nigwekar SU et al. – The authors identified 19 studies (11 prevention and 8 treatment) using low or high dose atrial natriuretic peptide (ANP), enrolling 1,861 patients. There was no difference in the number of deaths between ANP and control for studies preventing or treating AKI. The need for dialysis was significantly lower in both the low dose ANP treatment and prevention studies as well as for patients undergoing major surgery. The length of time spend in hospital and ICU was shorter for patients receiving low dose ANP. High dose ANP was associated with more hypotension and cardiac arrhythmias in patients with established AKI. ANP may be associated with improved outcomes when used in low doses for preventing AKI and in managing postsurgery AKI. There were no significant adverse events in the prevention studies, however in the high dose ANP treatment studies there were significant increases in hypotension and arrhythmias.

<< Previous
Global drug development in cancer: a cross-sectional study of...

Next >>
Early induction of CREB activation and CREB-regulating signalling...